Navigation Links
Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
Date:6/25/2010

CAMBRIDGE, Mass., June 25 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression. Anti-GITR agents have been identified by the National Cancer Institute as having high potential for treating cancer.  The preclinical data were presented and recognized as a distinguished abstract at the annual meeting of the Federation of Clinical Immunology Societies in Boston, Massachusetts.

The data included in the presentation demonstrated that a murine analog of TRX518, which is an anti-GITR antibody, resulted in pronounced and durable immune responses to several antigens in mice. These data also showed that the TRX518 analog, when combined with gemcitabine, a standard chemotherapeutic, significantly reduced tumor burden (p<0.001) and prolonged survival (p<0.001) in the mouse model when compared with gemcitabine alone. In particular, of the mice treated with the combination therapy, 65% had a complete remission. Similar findings were observed when the TRX518 analog was combined with cyclophosphamide. The humanized monoclonal antibody, TRX518, blocked the interaction of GITR with its ligand, enhanced the cytotoxicity of human natural killer cells, downmodulated GITR on peripheral blood lympocytes, did not induce appreciable cytokine release, and was well tolerated and safe at high doses in non-human primates.

"We are highly encouraged by the preclinical results with anti-GITR immunotherapy. This approach appears to induce unique mechanisms for augmenting antitumor immune responses and holds promise for treating malignancies in man," said Louis Vaickus, MD, Chief Medical Officer at Tolerx. "In a murine model of established colon cancer, the results, especially the complete remissions, were striking and these findings represent preclinical proof of concept for TRX518."

About TRX518

TRX518 is a targeted T-cell immunomodulator that binds to the glucocorticoid-induced tumor necrosis factor receptor (GITR) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the antitumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function and preclinical models suggest TRX518 may have a reduced risk of causing the serious inflammatory side effects that can result from cytokine release.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three preclinical candidates, TRX518, TRX585, and TRX385, which enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
2. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
10. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, Inc. ... company specializing in the treatment of non-melanoma skin ... with superficial radiation therapy, today announced that it ... 2016 financial results on Thursday, February 2, 2017 after ... hold a conference call with the investment community ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Source ... botanicals and 100 percent pure essential oils, announced the company had a successful visit ... , The annual ECRM event gives companies that work in the nutritional, sports and ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
Breaking Medicine News(10 mins):